Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | SCLC | Letter to the Editor

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting

Authors: Chenyue Zhang, Kai Wang, Haiyong Wang

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Excerpt

Genes have two alleles or copies, with one inherited from each parent. The loss of one of these gene copies, termed as loss of heterozygosity (LOH), is one of the most common genetic alterations in cancer [1]. LOH has been playing a pivotal role in cancer development [2]. For instance, LOH was found to be involved in the relapse of acute lymphoblastic leukemia [3]. LOH of human leukocyte antigen (HLA) alleles hampered the ability of major histocompatibility complex to present neoantigens, thus implicating in resistance to immune checkpoint blockade (ICB) therapy [4]. Therefore, expounding the relationship between LOH and cancer will be very helpful to guide the accurate treatment. …
Appendix
Available only for authorised users
Literature
1.
Zhang X, Sjöblom T. Targeting loss of heterozygosity: a novel paradigm for cancer therapy. Pharmaceuticals. 2021;14(1):57.CrossRef
2.
Tapial S, García JL, Corchete L, Holowatyj AN, Pérez J, Rueda D, Urioste M, González-Sarmiento R, Perea J. Copy neutral loss of heterozygosity (cnLOH) patterns in synchronous colorectal cancer. Eur J Hum Genet. 2021;29(4):709–13.CrossRef
3.
Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–6.CrossRef
4.
Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342.CrossRef
5.
Dawkins JBN, Webster RM. The small-cell lung cancer drug market. Nat Rev Drug Discov. 2020;19(8):507–8.CrossRef
6.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef
Metadata
Title
Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
Authors
Chenyue Zhang
Kai Wang
Haiyong Wang
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
SCLC
SCLC
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03019-6

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Research

LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1

Review

The roles and mechanisms of hypoxia in liver fibrosis

Research

Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans

Correction

Correction to: Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis

Correction

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Research

Model for in-vivo estimation of stiffness of tibiofemoral joint using MR imaging and FEM analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits